HVTN 111

A phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants,

Enrollment Opened

Objectives

-To evaluate safety and tolerability of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

-To evaluate  immune responses of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

Trial design

Multicenter, randomized, controlled, double-blind trial conducted in six sites in Southern African countries.

Funder/Sponsor

NIH/DAIDS HVTN

 

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya We're pleased to have @mgaya_prof, our NIMR DG on official visit to our NIMR Mbeya Centre, collaborators and Mobile… https://t.co/Rn7QD0DTNo
NIMRMbeya An eye opening session with Dr Adam Kilungu (MD, MMED Haematology) from the Mbeya Zonal Referral Hospital who prese… https://t.co/oSuSB747Tw
NIMRMbeya We were delighted having Dr David Mnzava (Medical registrar) and Dr Mashauri (CPD coordinator) from the Medical Co… https://t.co/DOrrhaeKx3
NIMRMbeya Dissemination workshop of the @EDCTP funded LIFE study, Mbeya Tanzania: Discussion with key health stakeholders on… https://t.co/T4r5VSoMMX
NIMRMbeya We're greatly honored by your visit,@USAmbTanzania. We're proud of the insightful discussion on the key health rese… https://t.co/blRVP2RFy4
© 2017 NIMR - Mbeya Medical Research Center